CID-103

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameCID-103
Drug Alias NameCID-103TSK011010
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsRejection of renal transplantationThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTusk Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKaixin Pharmaceuticals IncCasi Pharmaceuticals IncCASI Pharmaceuticals (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A